Non-Hodgkin’s Lymphoma - Investigational Targeted Therapy May Offer
Medical News Today - Data offers evidence that an investigational targeted therapy may be useful in treating patients with the most common form of non-Hodgkin’s lymphoma (NHL). The five-year survival rate of U.S. patients with NHL is only 59 percent with standard